Literature DB >> 24114580

Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non-kidney-related phenotypes.

Rainer Büscher1, Anja K Büscher, Stefanie Weber, Julia Mohr, Bianca Hegen, Udo Vester, Peter F Hoyer.   

Abstract

Autosomal recessive polycystic kidney disease (ARPKD), although less frequent than the dominant form, is a common, inherited ciliopathy of childhood that is caused by mutations in the PKHD1-gene on chromosome 6. The characteristic dilatation of the renal collecting ducts starts in utero and can present at any stage from infancy to adulthood. Renal insufficiency may already begin in utero and may lead to early abortion or oligohydramnios and lung hypoplasia in the newborn. However, there are also affected children who have no evidence of renal dysfunction in utero and who are born with normal renal function. Up to 30 % of patients die in the perinatal period, and those surviving the neonatal period reach end stage renal disease (ESRD) in infancy, early childhood or adolescence. In contrast, some affected patients have been diagnosed as adults with renal function ranging from normal to moderate renal insufficiency to ESRD. The clinical spectrum of ARPKD is broader than previously recognized. While bilateral renal enlargement with microcystic dilatation is the predominant clinical feature, arterial hypertension, intrahepatic biliary dysgenesis remain important manifestations that affect approximately 45 % of infants. All patients with ARPKD develop clinical findings of congenital hepatic fibrosis (CHF); however, non-obstructive dilation of the intrahepatic bile ducts in the liver (Caroli's disease) is seen at the histological level in only a subset of patients. Cholangitis and variceal bleeding, sequelae of portal hypertension, are life-threatening complications that may occur more often in advanced cases of liver disease. In this review we focus on common and uncommon kidney-related and non-kidney-related phenotypes. Clinical management of ARPKD patients should include consideration of potential problems related to these manifestations.

Entities:  

Mesh:

Year:  2013        PMID: 24114580     DOI: 10.1007/s00467-013-2634-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  52 in total

Review 1.  Genetics and pathogenesis of polycystic kidney disease.

Authors:  Peter Igarashi; Stefan Somlo
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

2.  Nephrectomy in an autosomal recessive polycystic kidney disease (ARPKD) patient with rapid kidney enlargement and increased expression of EGFR.

Authors:  Anja Arbeiter; Rainer Büscher; Klaus-Eugen Bonzel; Anne-Margret Wingen; Udo Vester; Jeremias Wohlschläger; Klaus Zerres; Jens Nürnberger; Carsten Bergmann; Peter F Hoyer
Journal:  Nephrol Dial Transplant       Date:  2008-05-23       Impact factor: 5.992

Review 3.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; P A Gabow
Journal:  Kidney Int Suppl       Date:  1997-10       Impact factor: 10.545

Review 4.  New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications.

Authors:  Grzegorz Telega; David Cronin; Ellis D Avner
Journal:  Pediatr Transplant       Date:  2013-04-17

5.  [Intrahepatic biliary cystic lesions].

Authors:  Catherine Guettier
Journal:  Ann Pathol       Date:  2010-11-27       Impact factor: 0.407

6.  Boy with autosomal recessive polycystic kidney and autosomal dominant polycystic liver disease.

Authors:  Andrea Zingg-Schenk; Jürg Caduff; Silvia Azzarello-Burri; Carsten Bergmann; Joost P H Drenth; Thomas J Neuhaus
Journal:  Pediatr Nephrol       Date:  2012-03-14       Impact factor: 3.714

7.  Autosomal recessive polycystic kidney disease: the clinical experience in North America.

Authors:  Lisa M Guay-Woodford; Renee A Desmond
Journal:  Pediatrics       Date:  2003-05       Impact factor: 7.124

Review 8.  Cystic renal diseases in children.

Authors:  M F Gagnadoux; R Habib; M Levy; F Brunelle; M Broyer
Journal:  Adv Nephrol Necker Hosp       Date:  1989

9.  Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Sergio A Gradilone; Bing Huang; Anatoliy I Masyuk; Marie C Hogan; Vicente E Torres; Nicholas F Larusso
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

10.  Abnormal lung development precedes oligohydramnios in a transgenic murine model of renal dysgenesis.

Authors:  N P Smith; P D Losty; M G Connell; U Mayer; E C Jesudason
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

View more
  21 in total

Review 1.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

Review 2.  Liver involvement in kidney disease and vice versa.

Authors:  Karen Van Hoeve; Djalila Mekahli; Eva Morava; Elena Levtchenko; Peter Witters
Journal:  Pediatr Nephrol       Date:  2017-06-23       Impact factor: 3.714

Review 3.  Transplantation in autosomal recessive polycystic kidney disease: liver and/or kidney?

Authors:  Jayanthi Chandar; Jennifer Garcia; Lydia Jorge; Akin Tekin
Journal:  Pediatr Nephrol       Date:  2014-08-13       Impact factor: 3.714

4.  Aberrant transcriptional regulation could explain phenotypic variability in autosomal recessive polycystic kidney disease.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2014-10       Impact factor: 4.599

Review 5.  Fibrocystic liver disease: novel concepts and translational perspectives.

Authors:  Alberto Lasagni; Massimiliano Cadamuro; Giovanni Morana; Luca Fabris; Mario Strazzabosco
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 6.  The causes and consequences of paediatric kidney disease on adult nephrology care.

Authors:  Ruth J Pepper; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2021-08-13       Impact factor: 3.651

7.  Impaired Hedgehog-Gli1 Pathway Activity Underlies the Vascular Phenotype of Polycystic Kidney Disease.

Authors:  Federico Franchi; Karen M Peterson; Katherine Quandt; David Domnick; Timothy L Kline; Michaela Olthoff; Mojtaba Parvizi; Ezequiel J Tolosa; Vicente E Torres; Peter C Harris; Martin E Fernandez-Zapico; Martin G Rodriguez-Porcel
Journal:  Hypertension       Date:  2020-10-05       Impact factor: 10.190

Review 8.  Autosomal Recessive Polycystic Kidney Disease-The Clinical Aspects and Diagnostic Challenges.

Authors:  Dorota Wicher; Łukasz Obrycki; Irena Jankowska
Journal:  J Pediatr Genet       Date:  2020-07-29

Review 9.  Polycystic Liver Disease: Advances in Understanding and Treatment.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Annu Rev Pathol       Date:  2021-11-01       Impact factor: 23.472

10.  Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C.

Authors:  Lijun Sun; Jiaqi Zhu; Ming Wu; Haipeng Sun; Chenchen Zhou; Lili Fu; Chenggang Xu; Changlin Mei
Journal:  Med Sci Monit       Date:  2015-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.